Features of proliferation and in vitro drug resistance in central primitive neuro-ectodermal tumours

Neuropathology and Applied Neurobiology

Volumn 28, Issue 3, 2002, Pages 200-209

  Schouten Van Meeteren, A Y N ^a   Van Der Valk, P ^a   Van Der Linden, H C ^a   Van Ouwerkerk, W J R ^a   Broekhuizen, A J F ^a   Huismans, D R ^a   Loonen, A H ^a   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell cycle; Central primitive neuro ectodermal tumour; Chemotherapy; Cyclin D1; DNA ploidy; Histopathology; In vitro drug resistance; Ki 67; MTT assay; PCNA; Proliferation; S phase

Indexed keywords

3,4,5 DIMETHYLTHIAZOL 2 YL 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROMINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLIN D; CYCLINE; CYTARABINE; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; KI 67 ANTIGEN; THIOTEPA; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER TISSUE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; PLOIDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; NEUROECTODERMAL TUMORS, PRIMITIVE;

EID: 0036284886     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2002.00387.x     Document Type: Article

References (43)

1. A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors
2. Proliferating cell nuclear antigen expression in central nervous system neoplasms
3. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children
4. Cyclin D1 expression in gliomas
5. Phase II study of ifosfamide in childhood brain tumors: A report by the French Society of Pediatric Oncology (SFOP)
6. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases
7. Current concepts in neurooncology: The cell cycle - A review
8. Do anticancer agents reach the tumor target in the human brain?
9. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors
10. Cyclophosphamide resistance in medulloblastoma
11. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents
12. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
13. Cellular proliferation in pilocytic and diffuse astrocytomas
14. Mitotic percentage index: A new prognostic factor for childhood medulloblastoma
15. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: A pediatric oncology group study
16. Cell kinetics of medulloblastomas
17. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours
18. High-dose chemotherapy in childhood brain tumours
19. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay
20. Chemosensitivity in childhood brain tumours in vitro. Evidence of differential sensitivity to lomustine (CCNU) and vincristine
21. Diagnostic markers in paediatric medulloblastoma: A paediatric oncology group study
22. Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma
23. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma
24. The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II. Evaluation of patient- and drug-specific variables
25. The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I. Evaluation of test-specific variables
26. Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods
27. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: An update
28. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A children's cancer group study
29. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions
30. Proliferation index as a predictor of prognosis in malignant gliomas of childhood
31. Proliferative potential and outcome in pediatric astrocytic tumors
32. Infrequent alterations of the p15, 16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors
33. Ki67 structure, function, and new antibodies
34. Tumor cell proliferation and apoptosis in medulloblastoma
35. Proliferative potential of brain tumors
36. Ploidy and proliferative index in medulloblastoma: Useful prognostic factors?
37. Bone metastases of medulloblastoma in childhood: Correlation with flow cytometric DNA analysis
38. Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas
39. The cycling pool of cells within human brain tumors: In situ cytokinetics using the monoclonal antibody Ki-67
40. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis
41. Prognostic significance of Ki-67 labelling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas
42. Prognostic importance of DNA ploidy in medulloblastoma in childhood
43. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children